New England Journal of Medicine · 1982 · 298 citations · 16 references
PharmacyPharmacologyPharmacotherapyBiochemical PharmacologyCardiovascular PharmacotherapyClinical PharmacologyCardiovascular Drug SafetySafety PharmacologyAcute Digoxin ToxicityCardiac Glycoside TherapyCardiac OutputDigitalis ToxicityDigoxin Fab Antibody TherapyFab Antibody FragmentsGlycoside ToxicitySuicidal Ingestion
Purified Fab fragments of digoxin-specific antibodies obtained from sheep were used to treat 26 patients with advanced, life-threatening digoxin (23 cases) or digitoxin (3 cases) toxicity. These patients had advanced cardiac arrhythmias, and in some cases hyperkalemia, which were resistant to conventional treatment. All patients had an initial favorable response to doses of Fab fragments calculated (in most cases) to be equivalent, on a molar basis, to the amount of cardiac glycoside in the patient's body. In four patients treated after prolonged hypotension and low cardiac output, death ensued from cerebral or myocardial hypoperfusion. In one case the available Fab fragment supply was inadequate to reverse a massive suicidal ingestion of digoxin, and the patient died after recurrent ventricular arrhythmias. In the remaining 21 patients, cardiac rhythm disturbances and hyperkalemia were rapidly reversed, and full recovery ensued. There were no adverse reactions to the treatment. We conclude that the use of purified digoxin-specific Fab fragments is a safe and effective means to reverse advanced, life-threatening digitalis intoxication.
16
V P Butler, J P Chen · Proceedings of the National Academy of Sciences · 1967 · 244 citations · Full text
Drugs Five Years Later: Naloxone
William R. Martin · Annals of Internal Medicine · 1976 · 139 citations